Clinical Trials on Refractory Lymphoma in Switzerland

Total 230 results

Cristiana Sessa

Completed

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma (IOSI-LND-001)

B-cell Lymphoma Refractory

Switzerland
University of Zurich

Unknown

Lymphoma in the Orbit

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Terminated

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
University Hospital Inselspital, Berne

Active, not recruiting

CD34+ Selected ASCT for Aggressive Lymphomas (SAAL)

Malignant Non-Hodgkin Lymphomas

Switzerland
Bristol-Myers Squibb

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed/Refractory Non-Hodgkin Lymphoma

United States, Spain, France, Netherlands, Switzerland
Kite, A Gilead Company

Recruiting

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)

Relapsed/Refractory Waldenstrom Macroglobulinemia | Relapsed/Refractory Richter Transformation | Relapsed/Refractory Burkitt Lymphoma | Relapsed/Refractory Hairy Cell Leukemia

United States, Spain, Germany, Italy, France, Netherlands, Switzerland, Austria
ADC Therapeutics S.A.

Terminated

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States, Belgium, Hungary, Israel, Spain, Switzerland, Poland, France, United Kingdom, Italy
International Extranodal Lymphoma Study Group (IELSG)

Completed

Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma

Splenic Marginal Zone Lymphoma

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Lymphoma, B Cell

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Lymphoma, B Cell

Switzerland
University Hospital, Geneva

Active, not recruiting

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma (FRILLY)

Aggressive B-Cell Non-Hodgkin Lymphoma

Switzerland
University of Zurich
University Hospital Inselspital, Berne; Swiss Paraplegic Centre Nottwil; Cantonal...

Completed

Sacral Neuromodulation for Neurogenic LUT Dysfunction

Refractory Neurogenic LUTD

Switzerland
Amgen

No longer available

Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (RIALTO)

Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia

United States, Italy, Germany, Austria, France, Switzerland, United Kingdom
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-Cell Lymphoma Refractory

United States, United Kingdom, Italy, Switzerland
University Hospital Inselspital, Berne
Hanusk Krankenhaus Wien

Completed

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) (BEB)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell

Switzerland, Austria
Kite, A Gilead Company

Active, not recruiting

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

United States, Spain, United Kingdom, Canada, Netherlands, Germany, France, Sweden, Israel, Switzerland, Belgium, Australia, Austria, Italy
University Hospital, Basel, Switzerland

Completed

Refractory Status Epilepticus Treatment: Quality and Efficacy of Coma Induction (RESET)

Status Epilepticus | Refractory Status Epilepticus

Switzerland
European Organisation for Research and Treatment...
Mallinckrodt

Withdrawn

Study of Photopheresis in the Treatment of Erythrodermic MF and SS (PROMPT)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Non-Hodgkin Lymphoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Follicular Lymphoma

Switzerland
Oncology Institute of Southern Switzerland

Recruiting

Liquid Biopsy in Mature B-cell Tumors

Mature B-Cell Neoplasm

Switzerland
University Hospital, Basel, Switzerland

Withdrawn

Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain (IMPORTANCE)

Cancer Pain

Switzerland
Onxeo

Completed

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma

Austria, France, Germany, Switzerland
Merck KGaA, Darmstadt, Germany

Completed

EMD 521873 in Advanced Solid Tumors, MTD Finding

Non-Hodgkin Lymphoma

Germany, Switzerland
Oncology Institute of Southern Switzerland
Azienda Ospedaliero Universitaria Maggiore della Carita; Arcispedale Santa... and other collaborators

Active, not recruiting

Personalized Risk Stratification Model of Follicular Lymphoma Patients

Follicular Lymphoma

Italy, Switzerland
Swiss Pediatric Oncology Group
ALL SCTped Forum

Recruiting

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Acute Lymphoblastic Leukemia

Switzerland
European Organisation for Research and Treatment...
Hoffmann-La Roche

Terminated

PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) (PARCT)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

Spain, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)

Marginal Zone B-cell Lymphoma

Italy, Switzerland, Austria
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
University of Zurich

Completed

T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC)

Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer | Cutaneous Lymphoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma

Lymphoma

Switzerland
MEI Pharma, Inc.

Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone B Cell Lymphoma | High Grade Non-Hodgkin's Lymphoma

United States, Switzerland
Lymphoma Study Association
Fondation ARC

Terminated

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Switzerland, Belgium
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

Marginal Zone Lymphoma

Italy, Switzerland, Austria
ImmunoGen, Inc.

Completed

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

Refractory Childhood Hodgkin Lymphoma | Ann Arbor Stage I Childhood Hodgkin Lymphoma | Ann Arbor Stage II Childhood Hodgkin Lymphoma | Ann Arbor Stage III Childhood Hodgkin Lymphoma | Ann Arbor Stage IV Childhood Hodgkin Lymphoma

United States, Canada, Australia, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Nodal Marginal Zone Lymphoma

United States, Switzerland, Armenia, France, Italy
National Cancer Institute (NCI)

Completed

Raltitrexed in Treating Children With Refractory Acute Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Lymphoma, Mucosa-Associated Lymphoid Tissue

United Kingdom, France, Italy, Switzerland, Spain, Belgium
University Hospital, Basel, Switzerland

Completed

NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Neuroblastoma | Rhabdomyosarcoma

Switzerland, Germany
Swiss Group for Clinical Cancer Research

Completed

Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

Lymphoma

Switzerland
Lymphoma Study Association
Amgen

Terminated

ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)

Non-hodgkin Lymphoma, B Cell

Switzerland
Ethical Oncology Science

Completed

Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin | Solid Tumors

Switzerland, Italy
Transgene

Completed

Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

Lymphoma, B-Cell

United States, France, Switzerland
Lymphoma Study Association

Completed

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
Lymphoma Study Association

Completed

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma

B-Cell Lymphoma

France, Belgium, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae (IELSG27)

Non-Hodgkin Lymphoma

Spain, Italy, Switzerland, Chile
Lymphoma Study Association
Amgen

Completed

R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland

Clinical Trials on Refractory Lymphoma in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations